Introduction
ProGRP, the precursor of Gastrin-Releasing Peptide (GRP), is widely distributed in non-gastric tissues, neural fibers, the brain, and lung neuroendocrine cells. With variations in its partial amino acids, proGRP can be categorized into three bio-macromolecules, all sharing a common C-terminal sequence (31-98) and demonstrating stable expression in the plasma. This peptide is the product encoded by the GRP gene, and studies have validated that proGRP levels effectively mirror GRP levels and gene expression.
The diagnostic significance of ProGRP is particularly prominent in the field of cancer diagnostics, where it has shown a strong association with various malignancies. Recent research has highlighted the ability of ProGRP levels to accurately reflect GRP expression and its associated gene. Notably, ProGRP emerges as a valuable biomarker for the diagnosis and treatment of diverse cancers, including small-cell lung cancer, non-small-cell lung cancer, gastrointestinal tumors, small-cell esophageal cancer, and ovarian cancer.
The measurement of ProGRP levels in plasma offers a non-invasive avenue for assessing the presence and progression of these cancers. As a result, ProGRP stands out as a pivotal diagnostic tool, holding significant implications for early detection, prognosis, and the development of targeted treatment strategies within the field of oncology. Stay updated on the latest advancements in ProGRP research, as it continues to be a promising area for enhancing cancer diagnostics and improving patient outcomes.
Calibration curve and its sensitivity (CLIA)
Method comparison
Linearity (CLIA)
Repeatability
